Loncar Cancer Immunotherapy Index ETF Overview

With 1 ETF traded in the U.S. markets, Loncar Cancer Immunotherapy Index ETF gathers total assets under management of $17.68M. The average expense ratio is 0.79%. Loncar Cancer Immunotherapy Index ETF can be found in the following asset class:

  • Equity

Daily ETF Watch

China Biotech ETF Launches

Latest ETF to come to market aims to offer unique access to an emerging hot sector only one other ETF focuses on today.

Features and News

Balchunas On Free ETFs & UFO Sighting

Bloomberg ETF analyst discusses what’s going on with ETFs in 2018.

Features and News

6 New Thematic ETFs With Potential

These funds give investors exposure to niche areas of the market.

Features and News

How ISE Builds ETF Partnerships

The ISE isn’t just an options exchange; it’s now a mostly unseen player in the ETF industry.

ETF Report

New ETF Brands

This directory provides a comprehensive list of all the new players in the ETF space and their operations.

Features and News

Cancer ETF Redefines Biotech Investing

The hot segment could use more segmentation, Brad Loncar says.